North America emerged as the leading segment in terms of revenue share in the GLP-1 drugs biosimilars market owing to the high prevalence rates of obesity and diabetes, developed healthcare system, and rising uptake of biologics in the region
in TCC, GSTP1 should be considered as a potential therapeutic target This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Considering the preventive, protective, and therapeutic effectiveness of the herbal therapies, evaluation of efficacy and safety in clinical trials may also be promising in the future after further confirming effects of each extract type, interactions between the supplements, and synergism between products
If you have obesity and are considering treatments that can lead to significant weight loss, you may be wondering how the two leading options compare: bariatric surgery, which permanently alters the digestive tract, versus powerful new appetite-suppressing medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials
